3 Anti-Infectives and Gastro Brands Leader, Research-Driven Pharma Company and Contract Formulations Producer Stocks With a Strong Future Roadmap: Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab
- October 27, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab: ROE of 12.9% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 19.5%. Prices as of 26 Oct 2026.
Quick Answer
The three acute care brand, research and contract stocks to watch are Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab. Their return on equity ranges from 12.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 19.5%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Innova Captab has the fastest revenue growth at 19.5% a year. Prices are based on the 26 October 2026 close, and this article is educational, not investment advice.
Acute care brand, research and contract stocks give investors a way to track businesses that sit close to everyday demand in India. Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab cover an anti-infectives and gastro brands leader, a research-driven pharma company and a contract formulations producer.
This list covers three acute care brand, research and contract stocks with complete current figures: Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Acute Care Brand, Research and Contract Stocks?
Acute care brand, research and contract stocks are listed drug makers that lead in everyday brands, invest in new drug research and make formulations for other companies. Their earnings depend on prescriptions, launches, plant quality and outsourcing demand.
Acute Care Brand, Research and Contract Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Alkem Laboratories | 5,030 | 59,723 | 27.1 | 36.0 | 16.7 | 0.15 |
| Glenmark Pharmaceuticals | 2,225.8 | 60,103 | 33.4 | 35.7 | 28.1 | 0.06 |
| Innova Captab | 998.2 | 5,736 | 37.2 | 36.0 | 12.9 | 0.32 |
On valuation, Alkem Laboratories and Glenmark Pharmaceuticals trade at a P/E below the industry P/E, while Innova Captab trades above it, which reflects the growth the market already expects. Readers comparing acute care brand, research and contract stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Acute Care Brand, Research and Contract Stocks Have a Strong Roadmap in India?
Acute care brand, research and contract stocks have a strong roadmap in India because trusted brands, a wide product pipeline and outsourced manufacturing keep widening the revenue base.
- Brand trust. Acute care brands retain prescribers.
- Research arm. New drug work adds long-term options.
- Contract work. Other drug brands hire contract makers.
Why Alkem Laboratories Features Among These Acute Care Brand, Research and Contract Stocks
Among the acute care brand, research and contract stocks on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.
In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%.
Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.
Roadmap: Alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.
Why Glenmark Pharmaceuticals Features Among These Acute Care Brand, Research and Contract Stocks
Among the gastro and anti-infective brand shares on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.
The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.
Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore.
Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.
Why Innova Captab Features Among These Acute Care Brand, Research and Contract Stocks
Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.
Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%.
In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.
Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.
Alkem Laboratories vs Glenmark Pharmaceuticals vs Innova Captab on Key Financials
The table below sets the three acute care brand, research and contract stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Alkem Laboratories | 10,797 | 15,296 | 9.1% | 2,353 | 15.4% |
| Glenmark Pharmaceuticals | 12,472 | 17,443 | 8.7% | 1,362 | 7.8% |
| Innova Captab | 803 | 1,637 | 19.5% | 141 | 8.6% |
Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with acute care brand, research and contract stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Alkem Laboratories | 3,508 | 3,893 | 11.0% |
| Glenmark Pharmaceuticals | 3,291 | 4,084 | 24.1% |
| Innova Captab | 356 | 473 | 32.8% |
Key Risks to Check Before Investing in Acute Care Brand, Research and Contract Stocks
Every theme carries risks that deserve a check before any decision. For these acute care brand, research and contract stocks, the main points are: Long-term gastro and anti-infective brand shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices can fall.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter acute care brand, research and contract stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Acute Care Brand, Research and Contract Stocks
Acute care brand, research and contract stocks work best when investors track growth, valuation and return on equity side by side. Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab each have a clear plan to grow. Based on the 26 October 2026 close, Alkem Laboratories trades at Rs 5,030, Glenmark Pharmaceuticals at Rs 2,225.8 and Innova Captab at Rs 998.2. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these acute care brand, research and contract stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track acute care brand, research and contract stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are acute care brand, research and contract stocks?
Ans. Acute care brand, research and contract stocks are listed drug makers that lead in everyday brands, invest in new drug research and make formulations for other companies. Their earnings depend on prescriptions, launches, plant quality and outsourcing demand. This list looks at three of them, Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.
Which acute care brand, research and contract stocks are covered in this list?
Ans. This list covers Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab. Based on the 26 October 2026 close, Alkem Laboratories traded at Rs 5,030, Glenmark Pharmaceuticals at Rs 2,225.8 and Innova Captab at Rs 998.2. Their return on equity ranges from 12.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 19.5%.
Why do acute care brand, research and contract stocks have a strong future roadmap in India?
Ans. Acute care brand, research and contract stocks have a strong roadmap in India because trusted brands, a wide product pipeline and outsourced manufacturing keep widening the revenue base. The main drivers are as follows. Brand trust. Acute care brands retain prescribers. Research arm. New drug work adds long-term options. Contract work. Other drug brands hire contract makers. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Alkem Laboratories performed financially?
Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
How has Glenmark Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
How has Innova Captab performed financially?
Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
What risks should investors check before buying acute care brand, research and contract stocks?
Ans. Investors should check a few risks before buying acute care brand, research and contract stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices can fall. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of acute care brand, research and contract stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
